Consistent with our findings in cultured cancer cell lines (Figure 1) and tumor models (Figure 5) that NNMTlow/DNMT1high cancer cells are sensitive to OXPHOS inhibition, nonrecurrent CRAs (enriched with Berberine sensitive tumors) had significant lower NNMT but higher DNMT1 expression compared with recurrent CRAs (Berberine resistant ones) (Figure 6B,C). This evidence concerns the gene DNMT1 and cancer.